CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cbdl · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CBD Life Sciences Inc. (CBDL) measures how much investors pay for each dollar of the company's trailing earnings. CBDL's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CBD Life Sciences Inc.You CBDL | $0M | N/A | — | -$0.00 |
 Aoxing Pharmaceutical Company, Inc. AOXG | $0M | 51.76x | — | $0.00 |
 Eastgate Biotech Corp. ETBI | $6M | N/A | — | -$0.00 |
 Grapefruit USA, Inc. GPFT | $1M | N/A | — | -$0.00 |
 Hemp Naturals, Inc. HPMM | $0M | N/A | — | -$0.01 |
 Invion Limited IVIXF | $0M | N/A | — | -$0.08 |
 Juva Life Inc. JUVAF | $0M | N/A | — | -$0.06 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.00 | — | |
2024-12-31 FY2024 | — | $-0.00 | — | |
2023-12-31 FY2023 | — | $-0.00 | — | |
2022-12-31 FY2022 | — | $-0.00 | — | |
2021-12-31 FY2021 | — | $-0.00 | — | |
2020-12-31 FY2020 | — | $-0.00 | — | |
2019-12-31 FY2019 | — | $-0.01 | — | |
2014-12-31 FY2014 | — | $-428.18 | — | |
2013-12-31 FY2013 | — | $-2294.59 | — | |
2012-12-31 FY2012 | — | $-2405.14 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CBD Life Sciences Inc. (CBDL) measures how much investors pay for each dollar of the company's trailing earnings. CBDL's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.
Frequently asked questions
CBDL pe ratio · 6 questionsCBDL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via CBDL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CBD Life Sciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09